Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #264 on InflaRx NV (IFRX)
Fat Thor
07/18/19 4:25 PM
#265 RE: Fat Thor #264
our in depth post-hoc data analysis suggests a robust anti-inflammatory activity in the high dose IFX-1 treatment group across numerous efficacy measures which were not reflected by the HiSCR. The company has made significant efforts to research the available data set and has engaged with US and European experts to assist in the analysis and interpretation of these findings. Based on this, our team continues to work on the development of IFX-1 in HS. We look forward to discussions with the regulatory authorities upon completion of the open label extension portion of the ongoing SHINE study,” he added.